免疫表型为弥漫大B细胞型的原发中枢神经系统淋巴瘤患者的预后分析

目的:对免疫表型为弥漫大B细胞型的原发中枢神经系统淋巴瘤(PCNSL)患者的预后因素进行分析探讨。方法:选取2011年3月至2017年10月徐州医科大学附属医院收治的免疫表型为弥漫大B细胞型的PCNSL患者42例,综合分析不同治疗方法对其总生存期的影响。结果:42例表型为弥漫大B细胞型PCNSL患者的性别、年龄、初诊脑脊液蛋白量及替莫唑胺、利妥昔单抗应用与否对患者总生存时间无影响(P>0.05),而尽早发现、及时治疗及治疗中常规鞘注、应用甲氨蝶呤能有效延长PCNSL患者总生存期。结论:尽早明确PCNSL诊断及积极规范化治疗能明显延长患者生存时间,同时进一步强调了常规鞘注对于延长患者生存期的必要性。

Prognostic Analysis of Primary Central Nervous System Lymphoma Patients with Diffuse Large B-Cell Immunophenotype

Objective:To investigate the prognostic influencing factors of primary central nervous system lymphoma(PCNSL)patients with diffuse large B-cell immunophenotype.Methods:42 PCNSL patients with diffuse large B-cell lymphoma treated in our hospital from March 2011 to October 2017 were enrolled.The effects of different treatments on overall survival of patients were analyzied.Results:The analysis for 42 PCNSL patients with diffuse large B-cell immunophenotype showed that there was no effect of their clinical characteristics,such as sex,age,CSF protein content,treatment with and without temozolomide and rituximab on overall survival of the patients(P>0.05).And it was found that active treatment and the application of conventional intrathecal injection and methotrexate in the treatment could effectively prolong the overall survival time of patients.Conclusion:Early diagnosis of PCNSL and active standardized treatment can significantly prolong the survival time of patients,and it is further emphasized that the necessity of conventional intrathecal injection to prolong the survival of patients.